Cite
HARVARD Citation
Kümmel, S. et al. (n.d.). P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study. Breast. pp. S63-S64. [Online].